Home / Europe / Portugal / Life Sciences & Healthcare

Life Sciences & Healthcare

The Health and Pharmaceutics area, as well as medical devices, and the new branches of science such as biotechnology, raise several legal issues and show a high complexity and specificity.

Whatever your opportunities or challenges, our dedicated team understands and advises on your commercial needs and ensures support in a wide range of areas from advertising and promotion, public sector contracting, patent application, commercial and clinical trial agreements, and regulatory advice.

 

The diversity of entities involved in this sector, the existing regulation and the market's own operation require from the lawyers a strong knowledge of the specificities of this department. Our team works in particular within the following areas:

  • Regulation
  • Licensing
  • Finance / Mergers and acquisitions
  • Business restructuring
  • Litigation
  • Clinical Research
  • Distribution
  • Patents Protection and Enforcement
  • Labelling
  • Safety and Health
  • Competition
  • Public Offers
  • Environment

The Life Sciences & Healthcare team works with some of the best known brands in the market. We can help you shape your strategy, manage risks and make the most of opportunities. Your challenges and priorities are at the heart of what we do. We have a multidisciplinary team with a strong curriculum in the pharmaceutical area. We are well positioned to give an answer to the several intervening players in this sector.

“A global powerhouse with deep expertise in the healthcare and life sciences sector”, CMS earns a top position thanks to its genuine dedication to the field Delivering “strong knowledge of the applicable law”, significant practical experience” and a consistently thorough approach”.

Legal 500

This firm bristles with the talent and experience necessary for a comprehensive life sciences practice, and excels accordingly.
Core areas of strength include product liability and patent litigation, competition law, regulatory advice, commercial and corporate support.

Chambers & Partners

Feed

01/06/2022
CMS Next
What’s next? In a world of ever-ac­cel­er­at­ing change, stay­ing ahead of the curve and know­ing what’s next for your busi­ness or sec­tor is es­sen­tial.At CMS, we see ourselves not only as your leg­al ad­visers but also as your busi­ness part­ners. We work to­geth­er with you to not only re­solve cur­rent is­sues but to an­ti­cip­ate fu­ture chal­lenges and in­nov­ate to meet them.With our latest pub­lic­a­tion, CMS Next, our ex­perts will reg­u­larly of­fer you in­sights in­to and fresh per­spect­ives on a range of is­sues that busi­nesses have to deal with – from ESG agen­das to re­struc­tur­ing after the pan­dem­ic or fa­cing the di­git­al trans­form­a­tion. We will also share with you more about the work that we are do­ing for our cli­ents, help­ing them in­nov­ate, grow and mit­ig­ate risk.To be able to provide you with the best sup­port, we im­merse ourselves in your world to un­der­stand your leg­al needs and chal­lenges. However, it is equally im­port­ant that you know who we are and how we can work with you. So, we in­vite you to meet our ex­perts and catch a glimpse of what is hap­pen­ing in­side CMS.En­joy read­ing this pub­lic­a­tion, which we will up­date reg­u­larly with new con­tent.CMS Ex­ec­ut­ive Team
19/05/2022
Can­nabis law and le­gis­la­tion in Por­tugal
Med­ic­al use Un­der the Por­tuguese Law, the use of can­nabis for med­ic­al pur­poses is ad­miss­ible, provided the ne­ces­sary re­quire­ments and the man­dat­ory li­censes are ob­tained.The Por­tuguese leg­al frame­work...
08/04/2022
The Pro­posed Dir­ect­ive on Cor­por­ate Sus­tain­ab­il­ity Due Di­li­gence – a step...
The Pro­posed Dir­ect­ive on Cor­por­ate Sus­tain­ab­il­ity Due Di­li­gence (the “CSDD Pro­pos­al”), pub­lished on 23 Feb­ru­ary 2022, aims to im­pose ob­lig­a­tions on com­pan­ies, their sub­si­di­ar­ies and their value chains...
05/04/2022
Re­cent up­dates to the EPO Guidelines for Ex­am­in­a­tion rel­ev­ant to in­ven­tions...
An amended ver­sion of the EPO Guidelines for Ex­am­in­a­tion entered in­to force on 1 March 2022, su­per­sed­ing the edi­tion of March 2021. Here we re­view the up­dates rel­ev­ant to in­ven­tions in the field of bi­o­tech­no­logy...
17/02/2022
Sig­ni­fic­ant Con­sulta­tion on pro­posed re­vi­sions to REACH
Un­til 15 April 2022, the European Com­mis­sion (“EC”) is con­sult­ing on pro­posed re­vi­sions of REACH, (Reg­u­la­tion (EC) No 1907/2006 as amended), the corner­stone of EU chem­ic­als reg­u­la­tion. REACH aims...
01/02/2022
UPC: Is it fi­nally here?
New tem­por­ary pro­vi­sions at the European Pat­ent Of­fice re­lat­ing to the Unit­ary Pat­ent The European Pat­ent Of­fice (EPO) is­sued 3 new no­tices on 19 Janu­ary 2022 about the Unit­ary Pat­ent. They are:...
27/01/2022
Schrems II: Re­ac­tions to the judge­ment and the su­per­vis­ory au­thor­it­ies'...
“Schrems II”: Opin­ions of the su­per­vis­ory au­thor­it­ies on Schrems II and re­com­mend­a­tions on the im­ple­ment­a­tion of the judge­ment in in­ter­na­tion­al data trans­fers On 16 Ju­ly 2020, the Court of Justice...
01/12/2021
A piece of pat­ent his­tory has been made con­cern­ing pat­entab­il­ity of com­puter...
In March 2021 the En­larged Board of Ap­peal of the European Pat­ent Of­fice answered ques­tions con­cern­ing pat­entab­il­ity of com­puter soft­ware sim­u­la­tions in case G1/19.  A Tech­nic­al Board of Ap­peal has now...
10/11/2021
COV­ID and ViCo: The End?
En­larged Board of Ap­peal de­cision G1/21 Back­ground Fol­low­ing an EPO press re­lease on 16 Ju­ly 2021, the En­larged Board of Ap­peal’s (EBA) de­cision on video­con­fer­en­cing (ViCo) was re­leased last week. We...
28/10/2021
Back to Square one? Gen­er­al Court de­cision provides guid­ance on dis­tinct­ive­ness...
In a de­cision dated 20 Oc­to­ber 2021, the Gen­er­al Court of the European Uni­on (“GC”) has re­af­firmed the re­quire­ments for the re­gis­tra­tion of a com­pos­ite trade mark, i.e. one com­posed of both word and...
28/10/2021
Arm­chair in­ven­tions: plaus­ib­il­ity at the EPO
Will it get harder to use post-filed data at the European Pat­ent Of­fice (EPO)? The is­sue of plaus­ib­il­ity has now been form­ally re­ferred to the highest ju­di­cial au­thor­ity at the EPO to cla­ri­fy the cir­cum­stances...
17/09/2021
Vac­cine com­pens­a­tion re­gimes in Por­tugal
1. Are COV­ID-19 vac­cin­a­tions ob­lig­at­ory in your jur­is­dic­tion? Are you ex­pect­ing any le­gis­lat­ive changes to en­able man­dat­ory vac­cines for all or cer­tain people (e.g. health­care pro­fes­sion­als, pub­lic ser­vants...
Comparable